293 completed, 185 recruiting, 132 unknown, 73 not yet recruiting. 253 Phase 2, 145 Phase 3, 123 Phase 1, 105 Not applicable, 78 Phase 4.
Follow Glomerulonephritis: new trials by email Literature Review of Glomerulonephritis trials Research Report on Glomerulonephritis
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Study of NM8074 in Patients With Immunoglobulin A Nephropathy (IgAN) NM8074 - IgA Nephropathy | Phase 2 | Not yet recruiting | NovelMed Therapeutics | 10 | 2028-02-01 | 2026-04-13 |
| CRISPR-Edited Allogeneic Anti-CD19 CAR-T Cell Therapy, in Patients With Refractory Systemic Lupus Erythematosus (GALLOP) CB-010 - Systemic Lupus Erythematosus, Lupus | Phase 1 | Withdrawn | Caribou Biosciences, Inc. | 2027-12-01 | 2025-09-19 | |
| A Clinical Study Evaluating the Safety and Efficacy of GT719 Universal Cell Injection in the Treatment of Immune-mediated Kidney Diseases CD19-targeted iNKT Cell Injection - IgA Nephropathy (IgAN), Membranous Nephropathy | Early Phase 1 | Not yet recruiting | Grit Biotechnology | 30 | 2027-08-01 | 2026-09-11 |
| Pilot STUDY to Monitor Ex-vivo the Biological Effects of the C3 Inhibitor, PEGCETACOPLAN, on Activation of Complement in Fluid Phase and on Podocytes in Patients With C3G and Primary IC-MPGN Blood sample - Glomerulopathy, C3G | Not yet recruiting | Mario Negri Institute for Pharmacological Research | 25 | 2027-03-01 | 2026-10-29 | |
| To Assess the Efficacy and Safety of Pegcetacoplan for the Prevention of Recurrent C3G or Primary IC-MPGN in Kidney Transplant Recipients Pegcetacoplan - C3 Glomerulopathy (C3G), Primary Immune-Complex Membranoproliferative | Phase 3 | Not yet recruiting | Swedish Orphan Biovitrum | 30 | 2027-01-21 | 2026-10-27 |
| A Study to Evaluate the Effectiveness and Safety of Sibeprenlimab in Participants With Primary Membranous Nephropathy, Immune-mediated Focal Segmental Glomerulosclerosis, and Minimal Change Disease Sibeprenlimab - Primary Membranous Nephropathy, Minimal Change Disease | Phase 2 | Not yet recruiting | Otsuka Pharmaceutical Development & Commercialization, Inc. | 20 | 2026-12-15 | 2026-10-06 |
| Efficacy and Safety of Obinutuzumab Beta in Primary IgA Nephropathy With Active Pathological Lesions Obinutuzumab Beta - Primary IgA Nephropathy | Phase 4 | Not yet recruiting | Ruijin Hospital | 20 | 2026-12-10 | 2026-10-22 |
| A Study of the Efficacy and Safety of Zigakibart + Atrasentan in Adult Patients With Primary IgA Nephropathy zigakibart, atrasentan, Placebo - IgA Nephropathy (IgAN) | Phase 3 | Not yet recruiting | Novartis Pharmaceuticals | 340 | 2026-12-01 | 2026-09-30 |
| A Phase 3 Blinded Study of JADE101 in Participants With Immunoglobulin A Nephropathy JADE101, Placebo - IgA Nephropathy (IgAN) | Phase 3 | Not yet recruiting | Jade Biosciences, Inc. | 480 | 2026-12-01 | 2026-10-29 |
| A Study to Learn About the Effects of Felzartamab on the Kidneys of Adults With Immunoglobulin A Nephropathy (IgAN) Felzartamab - Immunoglobulin A Nephropathy | Phase 2 | Not yet recruiting | Biogen | 25 | 2026-11-16 | 2026-10-22 |
| A Study to Evaluate the Effect of ARGX-121 on the Change in Proteinuria in Adult Participants With IgAN ARGX-121, Placebo - Immunoglobulin A Nephropathy (IgAN) | Phase 2 | Recruiting | argenx | 120 | 2026-11-05 | 2026-10-27 |
| An Open-Label Phase 2 Study of N-Acetyl-D-Mannosamine (ManNAc) in Subjects With Podocyte Diseases ManNAc - Focal Segmental Glomerulosclerosis, Minimal Change Disease | Phase 2 | Recruiting | National Human Genome Research Institute (NHGRI) | 30 | 2026-11-03 | 2026-10-29 |
| Optimizing Referral Pathways for Patients With Hematuria and Moderate-Severe Proteinuria Electronic Health Record alert - Referral and Consultation, Glomerulonephritis | Not applicable | Not yet recruiting | Geisinger Clinic | 1200 | 2026-11-01 | 2026-05-12 |
| Impact of Dapagliflozin for the Regulation of Immunological Activity in Membranous Nephropathy Forxiga - Glomerulonephritis | Phase 2 | Not yet recruiting | Centre Hospitalier Universitaire de Nice | 20 | 2026-11-01 | 2026-06-22 |
| Single-cell RNA Sequencing (scRNA-seq) to Investigate the Mechanisms Underlying the Induction of Regulatory T Cells in Patients With Extramembranous Glomerulonephritis Treated With Rituximab Peripheral blood immune-cell profiling by single-cell RNA sequencing and in vitro pathway modulation assays - Membranous Nephropathy, Membranous Nephropathy - PLA2R Induced | Not applicable | Not yet recruiting | Centre Hospitalier Universitaire de Nice | 12 | 2026-10-31 | 2026-09-10 |
| Trial of Sibeprenlimab in Children and Adolescents With Immunoglobulin A Nephropathy (IgAN) Sibeprenlimab, Standard of care - IgA Nephropathy | Phase 3 | Not yet recruiting | Otsuka Pharmaceutical Development & Commercialization, Inc. | 24 | 2026-10-30 | 2026-10-15 |
| A Study of BMS-986553 in Participants With Refractory Autoimmune Diseases BMS-986553 - Systemic Lupus Erythematosus, Sjögren's Disease | Phase 1 | Not yet recruiting | Bristol-Myers Squibb | 60 | 2026-10-30 | 2026-10-14 |
| A Phase 3b Study of Participant Experience on Povetacicept Administered Via Autoinjector as Compared to Sibeprenlimab Administered Via Prefilled Syringe Povetacicept, Sibeprenlimab - Immunoglobulin A Nephropathy | Phase 3 | Not yet recruiting | Vertex Pharmaceuticals Incorporated | 40 | 2026-10-23 | 2026-10-22 |
| MENA/Levant Epidemiological, Registry of Immunological & Clinical Traits (MERIT) Antiphospholipid (aPL)-Positive, Rheumatic Arthritis | Not yet recruiting | Axiom Bioregistry | 5000 | 2026-10-18 | 2026-10-23 | |
| IBI3034 Study in Healthy Adults and Patients With Primary IgA Nephropathy IBI3034, Placebo, Telitacicept - IgA Nephropathy (IgAN) | Phase 1 | Not yet recruiting | Innovent Biologics (Suzhou) Co. Ltd. | 100 | 2026-10-15 | 2026-10-21 |
Showing 20 of 843. Sign in to see all of them.
Lupus Nephritis (333) · Glomerulonephritis, IGA (271) · Lupus Erythematosus, Systemic (126) · Glomerulonephritis, Membranous (114) · Glomerulosclerosis, Focal Segmental (101) · Proteinuria (89) · Kidney Diseases (65) · Nephrotic Syndrome (52) · Nephrosis, Lipoid (48) · Autoimmune Diseases (42) · Renal Insufficiency, Chronic (42) · Glomerulonephritis, Membranoproliferative (32) · Nephritis (31) · Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis (22)
Female Urogenital Diseases (842) · Female Urogenital Diseases and Pregnancy Complications (842) · Male Urogenital Diseases (842) · Urogenital Diseases (837) · Urologic Diseases (827) · Nephritis (812) · Kidney Diseases (778) · Immune System Diseases (720) · Autoimmune Diseases (657) · Skin and Connective Tissue Diseases (361) · Connective Tissue Diseases (345) · Lupus Erythematosus, Systemic (212) · Pathological Conditions, Signs and Symptoms (166) · Signs and Symptoms (102)
Mycophenolic Acid (63) · Cyclophosphamide (59) · Prednisone (42) · Rituximab (42) · Tacrolimus (33) · Prednisolone (26) · Adrenal Cortex Hormones (21) · Methylprednisolone (17) · fludarabine (17) · Azathioprine (15) · voclosporin (12) · Cyclosporine (11) · Glucocorticoids (11) · Losartan (11) · telitacicept (11)
Novartis Pharmaceuticals (34) · Assiut University (25) · Nanjing University School of Medicine (15) · National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) (15) · Sun Yat-sen University (13) · Mario Negri Institute for Pharmacological Research (12) · Guangdong Provincial People's Hospital (11) · Aurinia Pharmaceuticals Inc. (9) · Mayo Clinic (9) · Alexion Pharmaceuticals, Inc. (8) · Assistance Publique - Hôpitaux de Paris (8) · Centre Hospitalier Universitaire de Nice (8) · Hoffmann-La Roche (8) · National Institute of Allergy and Infectious Diseases (NIAID) (8) · Peking University First Hospital (8)
United States (274) · China (262) · France (97) · Spain (91) · United Kingdom (89) · Italy (84) · Germany (79) · South Korea (76) · Australia (71) · Canada (63) · Taiwan (58) · Argentina (52) · Brazil (52) · Czechia (47) · Japan (47)
Radko Komers, MD, PhD (5) · Fernando C. Fervenza, M.D., Ph.D. (4) · Howard Trachtman, MD (4) · Jeffrey B Kopp, M.D. (4) · Yasar Caliskan, MD (4) · Zhihong Liu, Master (4) · Cheuk-Chun Szeto, MD (3) · David Wofsy, MD (3)
PMID 38299639, PMID 34778952, PMID 35224732, PMID 38724717, PMID 37528520, PMID 38864363, PMID 40465397, PMID 26032537, PMID 40337980, PMID 26630142, PMID 37772889, PMID 28763548, PMID 33693991, PMID 35230699, PMID 37254256, PMID 39513526, PMID 39899371, PMID 40938675, PMID 10093981, PMID 18930568, PMID 22087680, PMID 28341274, PMID 29450636, PMID 31340979, PMID 35675911, PMID 36423588, PMID 38334499, PMID 39331470, PMID 39455063, PMID 39673415, PMID 40444214, PMID 40482854, PMID 41092316, PMID 41442197, PMID 42133432, PMID 42175562, PMID 42275148, PMID 42384439, PMID 10676716, PMID 11511139, PMID 11877568, PMID 12209517, PMID 1356175, PMID 14694168, PMID 14989631, PMID 15807196, PMID 15851648, PMID 16014059, PMID 16164651, PMID 16881113
2023 (12), 2025 (8), 2018 (6), 2019 (6), 2017 (5), 2015 (4), 2014 (3), 2016 (3), R01DK131091 (2), R01DK141114 (2), U54DK083912 (2), 2005 (1), 2008 (1), 2009 (1), 5RC2DK122397 (1)